Evidence map›Paper›PMID 42549876›Full record

ArticleMicrobiology spectrum2026

Selection of effective LRAs using a newly designed

Alessia Neri, Arianna Rotili, Elena Morrocchi, Giuseppe Rubens Pascucci, Chiara Pighi, Giulio Olivieri, Federica Betto, Elena Emili, Ridika Karmakar, Daniela Iaconis and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Alessia Neri *PhD Program in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Rome, Italy.ORCID 0000-0002-6441-2800
Arianna Rotili *PhD Program in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Rome, Italy.ORCID 0009-0003-2272-5184
Elena MorrocchiClinical Immunology and Vaccinology Unit, IRCCS, Bambino Gesù Children's Hospital, Rome, Italy.
Giuseppe Rubens PascucciClinical Immunology and Vaccinology Unit, IRCCS, Bambino Gesù Children's Hospital, Rome, Italy.
Chiara PighiClinical Immunology and Vaccinology Unit, IRCCS, Bambino Gesù Children's Hospital, Rome, Italy.
Giulio OlivieriPhD Program in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Rome, Italy.
Federica BettoClinical Immunology and Vaccinology Unit, IRCCS, Bambino Gesù Children's Hospital, Rome, Italy.
Elena EmiliDepartment of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Ridika KarmakarDepartment of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Daniela IaconisEXSCALATE, Dompé Farmaceutici SpA, Naples, Italy.
Filippo LunghiniEXSCALATE, Dompé Farmaceutici SpA, Naples, Italy.
Gabriele CoppolaEXSCALATE, Dompé Farmaceutici SpA, Naples, Italy.
Donato AmodioClinical Immunology and Vaccinology Unit, IRCCS, Bambino Gesù Children's Hospital, Rome, Italy.
Nicola Cotugno *Clinical Immunology and Vaccinology Unit, IRCCS, Bambino Gesù Children's Hospital, Rome, Italy.
Paolo Palma *Clinical Immunology and Vaccinology Unit, IRCCS, Bambino Gesù Children's Hospital, Rome, Italy.ORCID 0000-0002-3066-4719

Funding

Pediatric Adolescent Virus Elimination (PAVE) Martin Delaney CollaboratoryUM1AI164566 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Ann M Chahroudi, Deborah Persaud · 2021 to 2026
$35.5M
NIAID NIH HHS UM1 AI164566NIH HHS 1UM1AI164566-01
6 · The paper itself

Abstract

Human immunodeficiency virus type 1 (HIV-1) persists in latent reservoirs, mainly within CD4 IMPORTANCE: This study addresses a major obstacle to curing human immunodeficiency virus type 1 (HIV-1) infection: the persistence of latent viral reservoirs that are not eliminated by current therapies. We developed a simple and reproducible assay to identify compounds capable of reactivating latent virus, a key step in cure strategies. Using this approach, we identified effective latency-reversing compounds and, through collaboration with Dompé using the EXSCALATE platform, we also identified Tandutinib as a promising new candidate for further investigation.

Indexed as

Anti-HIV AgentsHIV-1HIV InfectionsVirus ActivationVirus LatencyCD4-Positive T-LymphocytesCell LineDrug DiscoveryDrug Evaluation, PreclinicalFlow CytometryHumansAnti-HIV Agentscomputer-aided drug discoveryHIV curein vitro modelslatencylatency reversal

Identifiers

PMID42549876
PMCPMC13532288

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.